

NexoBrid®

Validated & commercialized


Globally approved: FDA, EMA, PMDA

12,000 patients treated to date



Emerging SOC for **Early, Effective and Selective Non-Surgical Eschar Removal** in Severe Burns

Eschar Removal is the **First Critical Step** in Burn Care



Prevents local infection and sepsis

Avoids further deterioration and scarring

Enables initiation of wound healing

Allows visual assessment of wound bed

Surgery is **Traumatic & Non-selective**



Loss of healthy tissue & blood


Challenging in delicate areas

Requires surgical team, operating room

NexoBrid significantly reduces need for surgery & improves patient outcomes Provides a disruptive Bioactive Therapy for Burn Care



Before



After

NexoBrid

- Bioactive therapy for burn care that significantly reduces need for surgery & improves patient outcomes
- A sterile mixture of proteolytic enzymes
- Easy to use, topical application, effectively removes eschar within 4 hours without harming viable tissue or blood loss
- Allows for early visual assessment of the wound

